Psoriasis
Conditions
Interventions
Mild and moderate group (group A - TCM internal treatment group):Jue Yin Granule+Moving cupping comfort therapy
Mild and moderate group (group B - TCM external treatment group):Jue Yin Granule placebo+Moving cupping therapy
Severe group ( group C - TCM treatment group):Jue Yin granules + Moving cupping therapy + NB-UVB comfort treatment
Severe group (group D - Western medicine treatment group):Jue Yin granules placebo +Moving cupping comfort therapy + NB-UVB
Severe group (E group - integrated Chinese and Western medicine treatment group):Jue Yin granules +Moving cupping therapy + NB-UVB
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Diagnostic criteria for psoriasis vulgaris; (2) Aged 18 and 65 years; (3) Consent to participate in the research study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with pustular psoriasis,arthrotype, erythroderma psoriasis and / or drip psoriasis; 2. Any clinically active skin diseases other than moderate to severe psoriasis vulgaris which might counter or influence the study aim; 3. Patients who used any of the following systemic treatments within 4 weeks before the Baseline visit eg: drugs for other studys, immuno-suppressive drugs, biologics; 4. Patients who used topical treatment within 2 weeks before the Baseline visit eg corticosteroids ultraviolet-light therapy including sunbathing; 5. Active infectious disease which was hard to control; 6. History of severe systemic disease. Or the clinical test index is one of the following: the ALT or the AST is higher than 1.5 times the normal value limit; the creatinine(Cr) is higher than 1.5 times the normal value limit; anyone of the main blood indicators (white blood cells count, red blood cells count, hemoglobin, platelet count) is lower than normal lower limit;or patients with other abnormal laboratory tests that the researchers judged unfit to participate in the trial; 7. A history of cancer and patients with primary or secondary immunodeficiency and hypersensitivity; 8. Participate in other clinical trials within 3 months prior to the baseline; 9. Received a major operation within 8 weeks prior to the baseline or study period; 10. women who have fertility refusal to adopt contraception from the screening period to the last time after the end of the drug delivery; 11. Pregnancy or lactation; 12. Subjects with smokehard-drinkingtake drugs and drug abuse; 13. Subjects with history or family history of severe psychosis; 14. Other subjects judged by the investigator to be ineligible for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| recurrence rate;BSA;VAS;DLQI;TCM clinical symptom assessment scale;PRQoL;Physician's Global Assessment; | — |
Countries
China
Contacts
Public ContactLi Bin
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed